Emergent BioSolutions Undertaking a $50-Million Expansion of its South Baltimore Facility

| May 29, 2019 | 0 Comments

Emergent BioSolutions Inc. is under construction on a $50-million expansion of its fill/finish facility at 1111 S. Paca St. in Pigtown/Carroll-Camden Industrial Area. The expansion is expected to be completed in 2021 and is anticipated to create up to 60 new jobs in the next couple of years.

Emergent develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats, existing and emerging infectious diseases, and opioid overdoses.

Emergent said the expansion will significantly increase the company’s contract development and manufacturing capacity, redundancy, and flexibility.

The project includes the addition of a new isolator enclosed fill line. Emergent has partnered with Groninger & Co. to install its FlexPro 50 filler with isolator technology and an integrated Christ lyophilizer. This entirely new line will have the capability of filling vials, syringes, and cartridges in a new fill suite with dedicated utilities.

The company will also be adding a second autoclave to provide manufacturing redundancy and increased sterilization capacity, a new cold storage space to support 2-8⁰c and -20⁰c requirements, new stability chambers, new media fill incubators, and additional warehousing and office space.

“The expansion of our Camden facility is a significant and impactful capital investment that will generate measurable benefits for our clients,” said Sean Kirk, senior vice president of manufacturing operations and CDMO business unit head, in a press release. “This investment in innovative and flexible technology not only expands our customer-centric offerings to support future growth, but also builds upon our history of quality to help ensure the utmost focus on patient safety in pursuit of our corporate mission – to protect and enhance life.”

“Emergent has a proven track record as a world-class provider of contract manufacturing services for both bulk drug substances and sterile injectable drug products,” said BJ Hull, vice president and general manager and site head at the Camden facility, in a press release. “This $50 million investment further demonstrates our commitment to meeting and exceeding the expectations of our customers as well as to stimulating economic growth and creating jobs in Baltimore.”

This was first reported in the Baltimore Business Journal.

About the Author:

Founder and Publisher of SouthBmore.com, longtime resident of South Baltimore, and a graduate of Towson University. Diehard Ravens and O's fan, beach volleyball enthusiast, dog lover, and "bar food" foodie. Email me at [email protected] and follow me on Twitter at @SoBoKevin.
×